menu
    • menu
    [{"orgOrder":0,"company":"Metsera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Metsera \/ ARCH Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Metsera","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"MET-097","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Metsera \/ Metsera","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ Metsera"},{"orgOrder":0,"company":"Metsera","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series B Financing","leadProduct":"Amylin Analog","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Metsera","amount2":0.22,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.22,"dosageForm":"","sponsorNew":"Metsera \/ Wellington Management","highestDevelopmentStatusID":"7","companyTruncated":"Metsera \/ Wellington Management"},{"orgOrder":0,"company":"Metsera","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Amylin Analog","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Metsera \/ Altasciences Company Inc","highestDevelopmentStatusID":"7","companyTruncated":"Metsera \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"MET-097i","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"}]

    Find Clinical Drug Pipeline Developments & Deals by Metsera

    Menu

    Metsera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MET097

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $316.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Metsera Closes IPO, Underwriters’ Option Fully Exercised

                            Details : The proceeds from the offering will used to fund the clinical development of MET097, which is being evalauted for the treatment of obesity.

                            Product Name : MET097

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 05, 2025

                            Lead Product(s) : MET097

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $316.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MET097

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $275.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Metsera Announces Pricing of Initial Public Offering

                            Details : The proceeds from the offering will used to fund the clinical development of MET097, which is being evalauted for the treatment of obesity.

                            Product Name : MET097

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 30, 2025

                            Lead Product(s) : MET097

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $275.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MET-097i

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metsera Announces Positive Phase 2a Data for GLP-1 Agonist MET-097i

                            Details : MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA), being investigated for obesity and overweight.

                            Product Name : MET-097i

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : MET-097i

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amylin Analog,MET-233i

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I/ Phase II

                            Sponsor : Altasciences Company Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity

                            Details : ET-097i is an ultra-long-acting injectable amylin analog, fully biased GLP-1 receptor agonist, being investigated in patients with obesity.

                            Product Name : MET-097i

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            November 21, 2024

                            Lead Product(s) : Amylin Analog,MET-233i

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Altasciences Company Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amylin Analog,MET-233i

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I/ Phase II

                            Sponsor : Wellington Management

                            Deal Size : $215.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio

                            Details : The proceeds will be used to further advance its portfolio of NuSH analog peptides, including MET-097i, a novel, fully-biased, potential once-monthly subcutaneously injectable GLP-1 RA.

                            Product Name : MET-097i

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : Amylin Analog,MET-233i

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Wellington Management

                            Deal Size : $215.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MET-097

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Recipient : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amneal and Metsera Announce Strategic Partnership for Obesity Medicines

                            Details : The collaboration aims to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, including MET-097, a GLP-1 receptor agonists and amylin receptor agonists.

                            Product Name : MET-097

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : MET-097

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Recipient : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Metsera

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : ARCH Venture Partners

                            Deal Size : $290 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Metsera Launches to Lead Next Generation Medicines for Obesity and Metabolic Diseases

                            Details : The proceeds will fund the development of oral and injectable incretin, non-incretin, and combination therapies, including injectable GLP-1 receptor agonists for obesity and metabolic diseases.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            April 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : ARCH Venture Partners

                            Deal Size : $290 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth